DK3524261T3 - Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt - Google Patents

Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt Download PDF

Info

Publication number
DK3524261T3
DK3524261T3 DK19163698.4T DK19163698T DK3524261T3 DK 3524261 T3 DK3524261 T3 DK 3524261T3 DK 19163698 T DK19163698 T DK 19163698T DK 3524261 T3 DK3524261 T3 DK 3524261T3
Authority
DK
Denmark
Prior art keywords
exendin
diabetes
reduction
treatment
body weight
Prior art date
Application number
DK19163698.4T
Other languages
English (en)
Inventor
Mark Fineman
Leigh Macconell
Kristin Taylor
Original Assignee
Amylin Pharmaceuticals Llc
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3524261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Llc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Llc
Application granted granted Critical
Publication of DK3524261T3 publication Critical patent/DK3524261T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
DK19163698.4T 2005-08-19 2006-08-18 Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt DK3524261T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70960405P 2005-08-19 2005-08-19
US77921606P 2006-03-03 2006-03-03
EP10016112.4A EP2347762B1 (en) 2005-08-19 2006-08-18 Exendin for treating diabetes and reducing body weight

Publications (1)

Publication Number Publication Date
DK3524261T3 true DK3524261T3 (da) 2024-01-15

Family

ID=37772212

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19163698.4T DK3524261T3 (da) 2005-08-19 2006-08-18 Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
DK06801867.0T DK1971362T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af legemsvægt
DK10016112.4T DK2347762T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af kropsvægt

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06801867.0T DK1971362T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af legemsvægt
DK10016112.4T DK2347762T3 (da) 2005-08-19 2006-08-18 Exendin til behandling af diabetes og reduktion af kropsvægt

Country Status (25)

Country Link
US (7) US20090239796A1 (da)
EP (3) EP1971362B1 (da)
JP (2) JP5693817B2 (da)
KR (1) KR101059279B1 (da)
CN (1) CN105056211A (da)
AU (2) AU2006283517B2 (da)
BR (1) BRPI0615358B8 (da)
CA (1) CA2619426C (da)
CY (1) CY1122010T1 (da)
DK (3) DK3524261T3 (da)
ES (2) ES2736184T3 (da)
FI (1) FI3524261T3 (da)
HR (1) HRP20150186T1 (da)
HU (1) HUE045165T2 (da)
IL (2) IL189607A (da)
LT (2) LT2347762T (da)
MX (1) MX2008002370A (da)
NZ (2) NZ566763A (da)
PL (2) PL2347762T3 (da)
PT (3) PT1971362E (da)
RS (1) RS53814B1 (da)
RU (1) RU2421237C2 (da)
SG (1) SG184730A1 (da)
SI (3) SI3524261T1 (da)
WO (1) WO2007024700A2 (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1617832T3 (da) 2003-04-29 2008-07-07 Orexigen Therapeutics Inc Præparater til påvirkning af vægttab
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ566763A (en) 2005-08-19 2011-06-30 Amylin Pharmaceuticals Inc Exendin-4 for treating diabetes, obesity and reducing body weight
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2303313B1 (en) * 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8895033B2 (en) 2008-09-04 2014-11-25 Amylin Pharmaceuticals, Llc Sustained release formulations using non-aqueous carriers
SI2349324T1 (en) 2008-10-17 2018-01-31 Sanofi-Aventis Deutschland Gmbh The combination of insulin and agonist GLP-1
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
CN109157742B (zh) 2009-08-03 2022-04-05 因卡伯实验室有限责任公司 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法
KR20150006083A (ko) 2009-09-28 2015-01-15 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
AR078973A1 (es) 2009-11-13 2011-12-14 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
US8562589B2 (en) * 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
EP2389945A1 (en) * 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
WO2012054817A1 (en) * 2010-10-22 2012-04-26 Mitokine Bioscience, Llc Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids)
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
ES2610362T3 (es) 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US10865419B2 (en) * 2011-10-24 2020-12-15 The Trustees Of The University Of Pennsylvania Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
DK2827845T3 (da) 2012-03-22 2019-04-01 Novo Nordisk As Sammensætninger omfattende et fremføringsmiddel og fremstilling deraf
ES2690553T3 (es) 2012-03-22 2018-11-21 Novo Nordisk A/S Composiciones de péptidos GLP-1 y preparación de estas
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE038748T2 (hu) 2012-12-21 2018-11-28 Sanofi Sa Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10105442B2 (en) 2014-05-07 2018-10-23 Novo Nordisk A/S Treatment of diabetes type 1 using GLP-1 and anti-IL-21
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212170A4 (en) 2014-11-02 2018-05-02 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2016164413A1 (en) 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
EP3297653B1 (en) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
KR101661332B1 (ko) * 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US20170098040A1 (en) * 2015-10-06 2017-04-06 Scale Down Weight management system and method
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017181007A1 (en) * 2016-04-15 2017-10-19 Robert Doyle Peptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
DK3570874T3 (da) * 2017-01-17 2023-04-11 Univ Wayne State Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder
KR20190126335A (ko) 2017-03-08 2019-11-11 인타르시아 세라퓨틱스 인코포레이티드 약물 전달 장치로부터 메스꺼움 유발 화합물을 투여하기 위한 장치 및 방법
EP3609577A4 (en) * 2017-04-14 2021-03-24 University of Massachusetts ADIPOKINS SELECTIVE TO BROWN FAT
CA3063183A1 (en) 2017-05-11 2019-12-03 Shenzhen Hightide Biopharmaceutical, Ltd. Use of peptide compounds in treating acute pancreatitis
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2019240755A1 (en) * 2018-06-11 2019-12-19 Wellesley Pharmaceuticals, Llc Pharmaceutical compositions and methods for weight loss
CN113164334A (zh) * 2018-10-12 2021-07-23 米拉基创新智库有限责任公司 用于减脂的低温溶液
MX2021004875A (es) * 2018-10-30 2021-08-11 Jianning Liu Polipeptido de peptido tipo glucagon (glp-1) que tiene actividad agonista de receptor del glp-1 y uso del mismo.
WO2021214023A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102556528B1 (ko) * 2020-12-08 2023-07-17 경희대학교 산학협력단 대사성 질환 예방, 개선 또는 치료용 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US386998A (en) 1888-07-31 Boiler
US3490597A (en) 1966-07-22 1970-01-20 Purolator Products Inc Cover plate for spin-on-filter
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5445781A (en) 1991-08-28 1995-08-29 Centro Sviluppo Settori Impiego S.R.L. Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
US5509305A (en) 1992-02-12 1996-04-23 Daniel Industries, Inc. Closely coupled, dual turbine volumetric flow meter
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
GB2282891B (en) 1993-10-13 1997-09-03 Tokai Rika Co Ltd Acceleration detecting apparatus
WO1995013799A1 (en) 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
ES2425559T5 (es) 1997-01-07 2018-02-02 Amylin Pharmaceuticals, Llc Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
EP1512395A1 (en) 1997-07-18 2005-03-09 Azopax Therapeutics LLC Biodegradable macromers for the controlled release of biologically active substances
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
ES2278589T3 (es) 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
NZ514916A (en) * 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
US6162260A (en) 1999-05-24 2000-12-19 Novo Nordisk Biochem North America, Inc. Single-bath biopreparation and dyeing of textiles
US20030036504A1 (en) 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US6602997B2 (en) 2000-04-27 2003-08-05 Shin-Etsu Bio, Inc. Whole cell and cell-debris polysaccharide
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2004521093A (ja) 2000-12-13 2004-07-15 イーライ・リリー・アンド・カンパニー グルカゴン様インスリン刺激性ペプチドを用いる長期治療計画
US6819912B2 (en) 2001-11-05 2004-11-16 Freescale Semiconductor, Inc. Variable frequency switching amplifier and method therefor
US7092459B2 (en) 2001-11-08 2006-08-15 Qualcomm, Incorporated Frequency tracking using pilot and non-pilot symbols
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
WO2004034975A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
US7164005B2 (en) 2002-10-17 2007-01-16 Alkermes, Inc. Microencapsulation and sustained release of biologically active polypeptides
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
WO2005040195A2 (en) 2003-10-24 2005-05-06 Azopax Therapeutics Llc Formulation of exendins
WO2005041873A2 (en) * 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP5030292B2 (ja) 2004-04-15 2012-09-19 アミリン・ファーマシューティカルズ，インコーポレイテッド ポリマーを基にした持続放出性装置
MXPA06013252A (es) 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
CA2566354C (en) 2004-05-28 2016-01-12 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
RU2390355C2 (ru) 2004-08-12 2010-05-27 Квест Фармасьютикал Сёвисес Фармацевтические композиции для доставки с регулируемым высвобождением биологически активных соединений
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
NZ566763A (en) 2005-08-19 2011-06-30 Amylin Pharmaceuticals Inc Exendin-4 for treating diabetes, obesity and reducing body weight
US7512298B2 (en) 2006-12-01 2009-03-31 3M Innovative Properties Company Optical sensing methods
IT1402944B1 (it) 2010-12-15 2013-09-27 Sarong Spa Capsula per bevande e relativa macchina per utilizzare detta capsula
US11638099B2 (en) 2011-12-23 2023-04-25 Shenzhen Shokz Co., Ltd. Bone conduction speaker and compound vibration device thereof
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (en) 2015-03-31 2023-08-01 Allen-Vanguard Corporation Frequency and time domain streaming receiver
US9714199B2 (en) 2015-09-17 2017-07-25 I P Creations Limited Concealed amalgamated explosive neutralizer and method of manufacture

Also Published As

Publication number Publication date
IL189607A0 (en) 2008-06-05
ES2526463T3 (es) 2015-01-12
US20110245162A1 (en) 2011-10-06
NZ593461A (en) 2013-01-25
SG184730A1 (en) 2012-10-30
HRP20150186T1 (hr) 2015-05-22
SI1971362T1 (sl) 2015-03-31
PT2347762T (pt) 2019-06-17
BRPI0615358B1 (pt) 2019-03-26
EP3524261A1 (en) 2019-08-14
PL2347762T3 (pl) 2019-09-30
IL189607A (en) 2016-10-31
BRPI0615358A2 (pt) 2011-05-17
CN105056211A (zh) 2015-11-18
EP1971362A2 (en) 2008-09-24
MX2008002370A (es) 2008-04-29
BRPI0615358B8 (pt) 2021-05-25
JP5693817B2 (ja) 2015-04-01
US8906851B2 (en) 2014-12-09
US20090239796A1 (en) 2009-09-24
SI3524261T1 (sl) 2024-02-29
LT3524261T (lt) 2024-04-10
AU2006283517A1 (en) 2007-03-01
DK1971362T3 (da) 2015-01-26
JP2015044831A (ja) 2015-03-12
RU2421237C2 (ru) 2011-06-20
US8329648B2 (en) 2012-12-11
PT1971362E (pt) 2015-02-10
PT3524261T (pt) 2024-01-12
US9884092B2 (en) 2018-02-06
CA2619426C (en) 2016-06-21
EP3524261B1 (en) 2023-12-13
EP1971362B1 (en) 2014-12-03
US20200222509A1 (en) 2020-07-16
WO2007024700A3 (en) 2007-08-09
NZ566763A (en) 2011-06-30
DK2347762T3 (da) 2019-06-11
RU2008110504A (ru) 2009-09-27
RS53814B1 (en) 2015-06-30
EP2347762A1 (en) 2011-07-27
CY1122010T1 (el) 2020-10-14
AU2011200663B2 (en) 2013-02-28
AU2006283517B2 (en) 2010-12-02
EP2347762B1 (en) 2019-05-08
JP2009504775A (ja) 2009-02-05
CA2619426A1 (en) 2007-03-01
AU2011200663A1 (en) 2011-03-10
WO2007024700A2 (en) 2007-03-01
KR101059279B1 (ko) 2011-08-24
US20130172243A1 (en) 2013-07-04
PL1971362T3 (pl) 2015-05-29
FI3524261T3 (fi) 2024-01-11
HUE045165T2 (hu) 2019-12-30
US20160271225A1 (en) 2016-09-22
WO2007024700A8 (en) 2007-12-27
SI2347762T1 (sl) 2019-09-30
ES2736184T3 (es) 2019-12-26
US20180333468A1 (en) 2018-11-22
IL243317A0 (en) 2016-02-29
KR20080038411A (ko) 2008-05-06
LT2347762T (lt) 2019-08-26
US20150150948A1 (en) 2015-06-04
JP5980872B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
DK3524261T3 (da) Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
EP1799263A4 (en) REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DE602006008834D1 (de) Binäre hyaluronsäure-gemische und ihre therapeutische verwendung
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
EP1899198A4 (en) LIBERABLE RETENTION MECHANISM AND METHOD OF USE
DK2124997T3 (da) Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
DK1848440T3 (da) Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
EP1928247A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
DK1812072T3 (da) Benzothiazol-præparat og anvendelse deraf
DK1598350T3 (da) Pyrrolidin- og thiazolidinforbindelser, fremgangsmåde til fremstilling heraf og deres anvendelse til behandling af hypoglykæmi og diabetes II
DK1940840T3 (da) 6-heteroarylpyridoindolon-derivater, fremstilling deraf og terapeutisk anvendelse deraf
EP1872126A4 (en) CD39L3 AND ITS ROLE IN DIABETES
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas
GB2442418B (en) Construction and use of shortened EG-LDPC codes
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0423173D0 (en) Treatment of diabetes
DK1962862T3 (da) Alkylphospholipidderivater med mindsket cytotoksicitet og anvendelser deraf